XIGDUO is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Dapagliflozin is indicated to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD) or multiple cardiovascular  (CV) risk factors.
| Trade Name | XIGDUO 1000mg |
|---|---|
| Generic Name | Dapagliflozin & Metformin HCL |
| Manufacturer | AstraZeneca Pharmaceuticals LP |
| Drug Type | cardiodiabetic |
| Indication | Antidiabetic |
| Doasage Form | Tablet |
| Packaging | 4 x 14tablets 5mg/1000mg |
